EU makes 1 billion-euro bet on Gilead's COVID drug before trial results

The European Union has agreed to pay more than 1 billion euros ($1.2 billion) to Gilead GILD.O for a six-month supply of its antiviral drug remdesivir, shortly before the publication of final results of the biggest trial of the COVID-19 medication.